

Special Issue

COVID-19, Neuroinflammation and Therapeutics, 2nd Edition

Message from the Guest Editor

With a continuously growing knowledge base due to information gathered from epidemiological studies, randomized controlled trials (RCTs), observational studies, case reports, and meta-analytical reviews, new light has been shed on different aspects of the direct and indirect disease burden associated with COVID-19. Although primarily a disease of the respiratory system, systematic inflammatory and immune responses have also emerged as a result of COVID-19; this indicates that its manifestations are diverse and affect multiple systems, including the nervous system. This Special Issue aims to fill knowledge gaps on COVID-19. We are inviting research papers, including reports, observational studies, RCTs, reviews (including narrative reviews), and meta-analytical reviews, that provide novel insights into the clinical features, treatments, therapeutics, and inflammatory biomarkers of COVID-19 (e.g., through laboratory-, neuroimaging-, or neurophysiology-based approaches). Bringing this new research to the forefront of the scientific community will enhance our understanding of this virus and its effects, especially those related to its neurological complications.

Guest Editor

Dr. Yasir Rehman

Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Deadline for manuscript submissions

closed (31 October 2024)



Neurology International

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.8
Indexed in PubMed



mdpi.com/si/188905

Neurology International
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
neuroint@mdpi.com

[mdpi.com/journal/
neuroint](https://mdpi.com/journal/neuroint)





Neurology International

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.8
Indexed in PubMed



[mdpi.com/journal/
neurolint](https://mdpi.com/journal/neurolint)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Junji Yamauchi

1. Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
2. Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Clinical Neurology)